Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
IB Acquisition Corp. ( (IBAC) ) has shared an announcement.
On March 16, 2026, GNQ Insilico Inc. and Nasdaq-listed SPAC IB Acquisition Corp. signed a definitive business combination agreement under which IB Acquisition will acquire all GNQ shares via a Canadian plan of arrangement, valuing GNQ at US$500 million. The deal, expected to close in the third quarter of 2026 subject to shareholder, court and regulatory approvals, is intended to list the combined company on Nasdaq with GNQ’s management team running the business and GNQ designating a majority of the post-merger board.
The transaction structure gives existing GNQ shareholders potential upside through revenue and share-price earnouts and is expected to deliver about US$15 million in proceeds to GNQ from a planned PIPE of up to US$10 million and IB Acquisition’s trust, while a concurrent bridge financing of up to US$2 million in convertible notes and warrants provides interim funding. Majority GNQ shareholders and the SPAC sponsor have entered into support and lock-up agreements, signaling alignment among key stakeholders as GNQ seeks to scale its AI- and quantum-enabled platforms, expand commercial partnerships and strengthen its position in the rapidly evolving precision medicine and drug development technology market.
More about IB Acquisition Corp.
GNQ Insilico Inc. is a Canadian TechBio company that aims to improve drug discovery and development by integrating artificial intelligence, quantum computing and advanced biological modeling. Its three proprietary platforms span drug assessment for life science investors, in silico drug simulation for pharmaceutical developers and digital twins for clinicians pursuing precision medicine.
IB Acquisition Corp. is a Nevada-based special purpose acquisition company listed on Nasdaq under the ticker IBAC, formed to identify and merge with innovative businesses. GNQ launched its Drug Assessment Platform in the fourth quarter of 2025, with its Drug Simulation and Digital Twins platforms planned for release later in 2026, positioning the firm at the nexus of AI-driven and quantum-enabled precision therapeutics.
Average Trading Volume: 5,832
Technical Sentiment Signal: Strong Buy
See more data about IBAC stock on TipRanks’ Stock Analysis page.